Buses To America? Tauzin Asks PhRMA Why It Does Business In Canada
Executive Summary
Restricting drug sales in Canada would send a strong signal about the consequences of price controls, House Commerce Committee Chairman Billy Tauzin (R-La.) told the Pharmaceutical Research & Manufacturers of America March 29 in Naples, Fla
You may also be interested in...
Lilly Rallies The Troops: Price Controls Would Trigger “Death Spiral”
Any erosion of free pricing or intellectual property protections in the U.S. pharmaceutical market would lead to a new wave of consolidation in the industry, Lilly CEO Sidney Taurel told the American Enterprise Institute March 18 in Washington, D.C
GSK Selling Direct To Canadian Pharmacies, Auditing Orders To Curb Imports
GlaxoSmithKline is selling its products direct to pharmacies in Canada that are suspected by the company of selling to consumers in the U.S
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011